Evidence map›Paper›PMID 18684948›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2008

The MHC class II-associated invariant chain interacts with the neonatal Fc gamma receptor and modulates its trafficking to endosomal/lysosomal compartments.

Lilin Ye, Xindong Liu, Subrat N Rout, Zili Li, Yongqi Yan, Li Lu, Tirumalai Kamala, Navreet K Nanda, Wenxia Song, Siba K Samal and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. The therapeutic age of the neonatal Fc receptor.Nature reviews. Immunology · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. The Role of FcRn in Antigen Presentation.Frontiers in immunology · 2014
    Review
  14. Pathways of antigen processing.Annual review of immunology · 2013
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Lilin YeLaboratory of Immunology, Virginia-Maryland Regional College of Veterinary Medicine, College Park, MD 20742, USA.
Xindong Liu
Subrat N Rout
Zili Li
Yongqi Yan
Li Lu
Tirumalai Kamala
Navreet K Nanda
Wenxia Song
Siba K Samal
Xiaoping Zhu
Laboratory of Molecular Genetics · PLVirginia–Maryland College of Veterinary Medicine · USBiogem · ITNational Institutes of Health · US

Funding

Transcytosis of IgG in Genital InfectionsR01AI065892 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI ZHU, XIAOPING · 2007 to 2010
$1.2M
The actin cytoskeleton in Beta cell activationR01AI059617 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI SONG, WENXIA · 2006 to 2009
$1.0M
AIDS Vaccine Strategy Using IgG Transfer PathwayR21AI073139 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI ZHU, XIAOPING · 2007 to 2008
$398k
Immunogenicity of Subunit Vaccine Delivered by FcRnR21AI067965 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI ZHU, XIAOPING · 2006 to 2007
$393k
Intramural NIH HHSNIAID NIH HHS AI59617NIAID NIH HHS AI65892NIAID NIH HHS AI67965NIAID NIH HHS AI73139NIAID NIH HHS N01-AO-6009NIAID NIH HHS R01 AI059617NIAID NIH HHS R01 AI065892NIAID NIH HHS R21 AI067965NIAID NIH HHS R21 AI073139
6 · The paper itself

Abstract

The neonatal Fc receptor for IgG (FcRn) transfers maternal IgG to the offspring and protects IgG from degradation. The FcRn resides in an acidic intracellular compartment, allowing it to bind IgG. In this study, we found the association of FcRn and invariant chain (Ii). The interaction was initiated within the endoplasmic reticulum by Ii binding to either the FcRn H chain alone or FcRn H chain-beta(2)-microglobulin complex and appeared to be maintained throughout the endocytic pathway. The CLIP in Ii was not required for FcRn-Ii association. The interaction was also detected in IFN-gamma-treated THP-1, epithelial and endothelial cells, and immature mouse DCs. A truncated FcRn without the cytoplasmic tail was unable to traffic to early endosomes; however, its location in early endosomes was restored by Ii expression. FcRn was also detected in the late endosome/lysosome only in the presence of Ii or on exposure to IFN-gamma. In immature human or mouse DCs, FcRn was barely detected in the late endosome/lysosome in the absence of Ii. Furthermore, the cytoplasmic tail of Ii conferred tailless FcRn to route to both the early endosome and late endosome/lysosome in a hybrid molecule. Because the FcRn is expressed in macrophages and DCs or epithelial and endothelial cells where Ii is induced under inflammation and infection, these results reveal the complexity of FcRn trafficking in which Ii is capable of expanding the boundary of FcRn trafficking. Taken together, the intracellular trafficking of FcRn is regulated by its intrinsic sorting information and/or an interaction with Ii chain.

Indexed as

Amino Acid SequenceAnimalsAntigens, Differentiation, B-LymphocyteCaco-2 CellsCell Line, TumorCHO CellsCricetinaeCricetulusEndosomesHeLa CellsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHT29 CellsHumansInflammation MediatorsLysosomesAntigens, Differentiation, B-LymphocyteFc receptor, neonatalHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInflammation Mediatorsinvariant chainReceptors, Fc

Identifiers

PMID18684948
PMCPMC2667114
OpenAlexW1954133219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.